欢迎来到《四川大学学报(医学版)》
马晚霞, 冉兴无. 新型冠状病毒肺炎的救治应重视血糖管理[J]. 四川大学学报(医学版), 2020, 51(2): 146-150. DOI: 10.12182/20200360606
引用本文: 马晚霞, 冉兴无. 新型冠状病毒肺炎的救治应重视血糖管理[J]. 四川大学学报(医学版), 2020, 51(2): 146-150. DOI: 10.12182/20200360606
MA Wan-xia, RAN Xing-wu. The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19[J]. Journal of Sichuan University (Medical Sciences), 2020, 51(2): 146-150. DOI: 10.12182/20200360606
Citation: MA Wan-xia, RAN Xing-wu. The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19[J]. Journal of Sichuan University (Medical Sciences), 2020, 51(2): 146-150. DOI: 10.12182/20200360606

新型冠状病毒肺炎的救治应重视血糖管理

The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19

  • 摘要: 新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)重症及死亡患者中有较高比例的高血糖或糖尿病患者,其救治更为困难,因此良好的血糖管理在COVID-19的综合救治过程中尤为重要。住院COVID-19合并糖尿病者可根据病情程度制定相应的血糖控制目标和治疗策略。轻型COVID-19患者,建议采取严格血糖控制目标(空腹血糖4.4~6.1 mmol/L,餐后2 h血糖6.1~7.8 mmol/L);普通型COVID-19患者,建议采取一般的血糖控制目标(空腹血糖6.1~7.8 mmol/L,餐后2 h血糖7.8~10.0 mmol/L),推荐应用皮下注射胰岛素治疗;重型或危重型COVID-19患者,建议采取相对宽松的血糖控制目标(空腹血糖7.8~10.0 mmol/L,餐后2 h血糖7.8~13.9 mmol/L),推荐采用静脉输注胰岛素治疗。由于部分患者病情变化迅速,在治疗过程中出现酮症酸中毒(diabetic ketoacidosis, DKA)或高血糖高渗状态(hyperglycemic hyperosmolar status,HHS)等,应加强血糖监测,动态评估,适时调整策略,进而保证患者安全,促进患者早日康复。

     

    Abstract: Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients.

     

© 2020 《四川大学学报(医学版)》编辑部 版权所有 cc

开放获取 本文遵循知识共享署名—非商业性使用4.0国际许可协议(CC BY-NC 4.0),允许第三方对本刊发表的论文自由共享(即在任何媒介以任何形式复制、发行原文)、演绎(即修改、转换或以原文为基础进行创作),必须给出适当的署名,提供指向本文许可协议的链接,同时标明是否对原文作了修改;不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问 https://creativecommons.org/licenses/by-nc/4.0

/

返回文章
返回